Odevixibat by Ipsen for Biliary Atresia: Likelihood of Approval

Odevixibat is under clinical development by Ipsen and currently in Phase III for Biliary Atresia.

Early detection of specific microRNAs may help predict preeclampsia in pregnant women

Preeclampsia (PE) is a significant contributor to the increase in maternal morbidity and mortality worldwide, with particularly alarming numbers in the United States, where it

July 16, 2024

BeiGene agrees with Novartis for global rights to TEVIMBRA

Novartis will offer transition services along with support to BeiGene. Credit: JHVEPhoto/Shutterstock.com. BeiGene has signed an agreement with Novartis to regain global rights related to

September 20, 2023

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis – Pharmaceutical Technology

Ulcerative colitis is inflammation of the lower end of the digestive system, including the large bowel and rectum. Credit: Emily frost via Shutterstock. Johnson &

November 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.